Business Description
Macrogenics Inc
NAICS : 325412
SIC : 2834
ISIN : US5560991094
Description
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.77 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | 16.84 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.58 | |||||
| Beneish M-Score | -4.99 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -20.9 | |||||
| 3-Year EPS without NRI Growth Rate | -1.6 | |||||
| 3-Year FCF Growth Rate | 16.9 | |||||
| 3-Year Book Growth Rate | -22.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.01 | |||||
| 9-Day RSI | 34.97 | |||||
| 14-Day RSI | 39.88 | |||||
| 6-1 Month Momentum % | 181.03 | |||||
| 12-1 Month Momentum % | 108.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.48 | |||||
| Quick Ratio | 4.46 | |||||
| Cash Ratio | 4.1 | |||||
| Days Inventory | 58.51 | |||||
| Days Sales Outstanding | 172.49 | |||||
| Days Payable | 197.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.3 | |||||
| Shareholder Yield % | -0.97 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 85.55 | |||||
| Operating Margin % | -295.63 | |||||
| Net Margin % | -15.92 | |||||
| FCF Margin % | -140.52 | |||||
| ROE % | -5.89 | |||||
| ROA % | -2.89 | |||||
| ROIC % | -226.99 | |||||
| ROC (Joel Greenblatt) % | -13.49 | |||||
| ROCE % | -2.89 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 17.97 | |||||
| PS Ratio | 15.67 | |||||
| PB Ratio | 5.92 | |||||
| Price-to-Tangible-Book | 5.92 | |||||
| EV-to-EBIT | -92.18 | |||||
| EV-to-EBITDA | 348.62 | |||||
| EV-to-Revenue | 12.36 | |||||
| EV-to-Forward-Revenue | 11.8 | |||||
| EV-to-FCF | -8.79 | |||||
| Price-to-Median-PS-Value | 1.91 | |||||
| Price-to-Net-Current-Asset-Value | 8.56 | |||||
| Price-to-Net-Cash | 10.79 | |||||
| Earnings Yield (Greenblatt) % | -1.08 | |||||
| FCF Yield % | -8.78 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers